CERS News and Press, Cerus Corporation From 11/08/21

Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Mo...

Cerus (CERS +17.5%) is up significantly today following the company's  Q3 2021 revenue and EPS beat after the bell yesterday. The company's net loss narrowed year over year from $14.1M, ($0.08 per basic and diluted share) in Q3 2020 to $12.4M ($0.07 per basic and diluted s...

Image source: The Motley Fool. Cerus Corporation (NASDAQ: CERS) Q3 2021 Earnings Call Nov 2, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Cerus Corporation (CERS) Q3 2021 Earnings Call Transcript

Cerus Corporation (CERS) Q3 2021 Earnings Conference Call November 2, 2021 4:30 PM ET Company Participants Matt Notarianni - Senior Director of Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Offic...

Cerus Corporation (NASDAQ:CERS) has added ~17.2% in the post-market after the company exceeded analyst expectations for revenue by as much as ~$10.5M with its Q3 2021. The maker of INTERCEPT Blood System also set its 2021 guidance ahead of Street forecasts. “Cerus’ thi...

Cerus (NASDAQ:CERS): Q3 GAAP EPS of -$0.07 beats by $0.03. Revenue of $42.1M (+44.2% Y/Y) beats by $10.47M. Shares +14%. Press Release For further details see: Cerus EPS beats by $0.03, beats on revenue

Accelerating Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $42.1 Million Grew 44% in the Third Quarter Product Revenue of $36.1 Million Grew 53% in the Third Quarter Full-Year 2021 Product Revenue Guidance Range Raised to $127-1...

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management ...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Today marks the effective date for the U.S. Food and Drug Administration’s (FDA) final guidance document on bacterial risk control strategies for platelet collection and transfusion. This guidance for industry, “Bacterial Risk Control Strategies for Blood Collection Establ...